Cardarine raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-02-07. Anything still debated is marked as such rather than presented as settled.
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Common for reference-grade material. |
| Solubility | Low in water | Dissolves in DMSO and some organic solvents. |
| Typical storage | -20 °C, desiccated | Protect from light and moisture. |
| Analytical method | LC-MS/MS | Used for trace detection in biological matrices. |
| Purity assessment | HPLC with UV detection | Often combined with NMR and mass spectrometry. |
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
18 February 1919: In spite of the ceasefire, there is fighting near Rynarzewo. The Poles capture the armoured train. 9 February 1919: A volunteer company of Great Polish soldiers moves to Lesser Poland to fight against the Ukrainians. 20 March 1919: The Ostmarkenzulage, a special allowance for German officials working in the eastern provinces to stimulate the German colonization of the Prussian Partition, is canceled. 23 March 1919: The Poles win a landslide in elections to the city council of Poznań. 24 March 1919: The Commission of the NRL asks the Polish government in Warsaw to create separate administration of the former Prussian Partition, as it is far more developed than the rest of the country. Ignacy Paderewski forces the government to leave all power in hands of the NRL until the final recognition of Polish-German border, with later autonomy there (only Upper Silesia would obtain it). The NRL mobilises men born in 1891, 1892, 1893, 1894 and 1901. 5 April 1919: The Sejm Ustawodawczy announces byelections in the former Province of Posen for next 42 MPs. 9 April 1919: The Commission of the NRL decrees an eight-hour workday in industry and trade. 10 April 1919: The Commission of the NRL decrees the removal of signs in German language from offices and train stations the changing of all streets names into Polish. The punishment for breaking the law is two years of prison and a fine of Mp. 10,000. 16 April 1919: The NRL decides that 3 May is the national holiday. 7 May 1919: The Wszechnica Piastowska is opened. 15 May 1919: Polish becomes the only official language.
== Further reading == Ballard, Mary, W (1991), IMPORTANT EARLY SYNTHETIC DYES Chemistry Constitution Date Properties, Smithsonian Institution{{citation}}: CS1 maint: multiple names: authors list (link) https://colourlex.com/ Venkataraman, K. (1971). The chemistry of synthetic dyes (Vol. 1, 5). New York: Academic Press.
=== Other species === FPR receptors are widely distributed throughout mammalian species with the FPR1, FPR2, and FPR3 paralogs, based on phylogenetic analysis, originating from a common ancestor and early duplication of FPR1 and FPR2/FPR3 splitting with FPR3 originating from the latest duplication event near the origin of primates. Rabbits express an ortholog of FPR1 (78% amino acid sequence identity) with high binding affinity for FMLP; rats express an ortholog of FPR2 (74% amino acid sequence identity) with high affinity for lipoxin A4.
Sheikh Muszaphar later regarded Mahathir as the 'father of Malaysia's space programme.' At UMNO's general assembly in 2002, he announced that he would resign as prime minister, only for supporters to rush to the stage and convince him tearfully to remain. He subsequently fixed his retirement for October 2003, giving him time to ensure an orderly and uncontroversial transition to his anointed successor, Abdullah Badawi. Mahathir simultaneously pledged that he would not take on an elder statesman role after retirement. During his final year in office, Mahathir introduced the teaching of Mathematics and Science in English (PPSMI) in 2003, believing that it is crucial for Malaysians to remain competitive in a fast-changing world. During the Severe Acute Respiratory Syndrome (SARS) outbreak, Mahathir introduced an RM8 billion stimulus package, contributing to Malaysia's 6.5% economic growth in the third quarter of 2003. The package focused on four main strategies and 90 measures to stimulate economic activity, boost consumption, and encourage investment. On 29 October 2003, the cabinet paid tribute to Mahathir for his invaluable service to the nation as prime minister for the last 22 years. He also received a record-breaking outpouring of public gratitude, marked by a 5.5 km-long banner displaying messages from over 50,000 Malaysians. The following day, Mahathir presented a review of Malaysia's five-year economic plan at Parliament House. Having spent over 22 years in office, Mahathir was the world's longest-serving elected leader when he retired on 31 October 2003.
Sources: en.wikipedia.org
=== Gene therapy === Researchers are working on a gene editing method to correct a mutation that leads to Duchenne muscular dystrophy (DMD). Researchers used a technique called CRISPR/Cas9-mediated genome editing, which can precisely remove a mutation in the dystrophin gene in DNA, allowing the body's DNA repair mechanisms to replace it with a normal copy of the gene. Genome editing through the CRISPR/Cas9 system is not currently feasible in humans. However, it may be possible, through advancements in technology, to use this technique to develop therapies for DMD in the future. In 2007, researchers did the world's first clinical (viral-mediated) gene therapy trial for Duchenne MD. Biostrophin is a delivery vector for gene therapy in the treatment of Duchenne muscular dystrophy and Becker muscular dystrophy.
Examples of landmark, and frequently controversial judgments, include Van Gend en Loos (holding EU law to created a new legal order, and citizens could sue for treaty rights), Mangold v Helm (establishing equality as a general principle of EU law), and Kadi v Commission (confirming international law had to conform with basic principles of EU law). Until 2016, there was the European Union Civil Service Tribunal, which dealt with EU institutions' staff issues.
=== PTEN hamartoma syndrome === PTEN hamartoma syndrome encompasses hamartomatous disorders characterized by genetic mutations in the PTEN tumor suppressor gene, including Cowden syndrome, Bannayan–Riley–Ruvalcaba syndrome, Proteus syndrome and Proteus-like syndrome. Absent or dysfunctional PTEN protein allows cells to over-proliferate, causing hamartomas. Cowden syndrome is an autosomal dominant genetic disorder characterized by multiple benign hamartomas (trichilemmomas and mucocutaneous papillomatous papules) as well as a predisposition for cancers of multiple organs including the breast and thyroid. Bannayan–Riley–Ruvalcaba syndrome is a congenital disorder characterized by hamartomatous intestinal polyposis, macrocephaly, lipomatosis, hemangiomatosis and glans penis macules. Proteus syndrome is characterized by nevi, asymmetric overgrowth of various body parts, adipose tissue dysregulation, cystadenomas, adenomas, vascular malformation.
Sources: en.wikipedia.org
MPEG LA is making claims that DisplayPort implementation requires a license and a royalty payment. It is important to note that these are only CLAIMS. Whether these CLAIMS are relevant will likely be decided in a US court. By March 2017, that statement had been removed from the official FAQ, while the various other references to being royalty-free were kept. By November 2018, mentions of DisplayPort being royalty-free were removed from the FAQ. While VESA does not charge any per-device royalty fees, VESA requires membership for access to said standards. The minimum cost is presently $5,000 (or $10,000 depending on Annual Corporate Sales Revenue) annually.
Methenamine is provided in the form of 500 and 1,000 mg oral tablets. It is available both alone and in combination with the nonsteroidal anti-inflammatory drug (NSAID) sodium salicylate. Other combinations with other drugs, such as phenazopyridine, are also available. Methenamine is provided pharmaceutically alone as the hippuric acid (methenamine hippurate) and mandelic acid (methenamine mandelate) salts. The free base and other salts, including anhydromethylencitrate and sulfosalicylate, have also been marketed in some countries. Methenamine mandelate is provided as an enteric coated tablet and is taken four times daily, whereas methenamine hippurate is available only in non-coated tablet form and is taken twice daily. Non-coated methenamine tablets can have a chemical taste described as sweet, sour, and/or metallic. Methenamine is available both by prescription (by itself) and over the counter (in combinations). Over-the-counter formulations in combination with sodium salicylate (162.5 mg) contain a lower amount of methenamine of 162 mg methenamine free base per tablet compared to prescription formulations and are taken three times daily.
==== Medical conditions ==== Undiagnosed maternal celiac disease may cause a short duration of the breastfeeding period. Treatment with the gluten-free diet can increase its duration and restore it to the average value of the healthy women. Mothers with all types of diabetes mellitus normally use insulin to control their blood sugar, as the safety of other antidiabetic drugs while breastfeeding is unknown. Women with polycystic ovary syndrome, which is associated with some hormonal differences and obesity, may have greater difficulty with producing a sufficient supply to support exclusive breastfeeding, especially during the first weeks.
=== Industrial sources === PFOA is released directly from industrial sites. For example, the estimate for the DuPont Washington Works facility is a total PFOA emissions of 80,000 pounds (lbs) in 2000 and 1,700 pounds in 2004. A 2006 study, with two of four authors being DuPont employees, estimated about 80% of historical perfluorocarboxylate emissions were released to the environment from fluoropolymer manufacture and use. PFOA can be measured in water from industrial sites other than fluorochemical plants. PFOA has also been detected in emissions from the carpet industry, paper and electronics industries. The most important emission sources are carpet and textile protection products, as well as fire-fighting foams.
Sources: en.wikipedia.org
LC-MS/MS is common, often after sample cleanup. The assay targets GW501516 or its metabolites.
Reference material is usually kept cold, dry, and protected from light. Frozen aliquots reduce repeated freeze-thaw cycles.
No approved pharmaceutical product exists, so manufacturing and quality controls are not standardized. Products may contain different compounds or impurities.
No. Cardarine has not received approval for human therapeutic use in major jurisdictions. It remains an investigational compound.